Cargando…
Evaluation of Surgical Therapy in Advanced Thymic Tumors
SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The prima...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471625/ https://www.ncbi.nlm.nih.gov/pubmed/34572742 http://dx.doi.org/10.3390/cancers13184516 |
_version_ | 1784574516000718848 |
---|---|
author | Markowiak, Till Ansari, Mohammed Khalid Afeen Neu, Reiner Schalke, Berthold Marx, Alexander Hofmann, Hans-Stefan Ried, Michael |
author_facet | Markowiak, Till Ansari, Mohammed Khalid Afeen Neu, Reiner Schalke, Berthold Marx, Alexander Hofmann, Hans-Stefan Ried, Michael |
author_sort | Markowiak, Till |
collection | PubMed |
description | SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, and survival. In tumor stages III a microscopic complete resection was achieved in 53.3% of patients. In stages IV a macroscopic complete resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. The 5-year survival rate of all patients was 61.3%. In particular, median survival after macroscopic incomplete resection was significantly short. Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. ABSTRACT: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, 73 patients with advanced thymic tumors of UICC stages III and IV who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, recurrence/progression-free, and overall survival. In total, 31.5% of patients were assigned to stage IIIa, 9.6% to stage IIIb, 47.9% to stage IVa, and 11% to stage IVb. In stages III a R0 resection was achieved in 53.3% of patients. In stages IV a R0/R1 resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. Median recurrence/progression-free interval was 43 months (p = 0.19) with an overall survival of 79 months. The 5-year survival rate was 61.3%, respectively. Median survival after R2 resection was 25 months, significantly shorter than after R0 or R1 resection (115 months; p = 0.004). Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. |
format | Online Article Text |
id | pubmed-8471625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84716252021-09-28 Evaluation of Surgical Therapy in Advanced Thymic Tumors Markowiak, Till Ansari, Mohammed Khalid Afeen Neu, Reiner Schalke, Berthold Marx, Alexander Hofmann, Hans-Stefan Ried, Michael Cancers (Basel) Article SIMPLE SUMMARY: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, patients with advanced thymic tumors who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, and survival. In tumor stages III a microscopic complete resection was achieved in 53.3% of patients. In stages IV a macroscopic complete resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. The 5-year survival rate of all patients was 61.3%. In particular, median survival after macroscopic incomplete resection was significantly short. Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. ABSTRACT: A complete resection of thymic tumors is known to be the most important prognostic factor, but it is often difficult to perform, especially in advanced stages. In this study, 73 patients with advanced thymic tumors of UICC stages III and IV who underwent radical resection were examined retrospectively. The primary endpoint was defined as the postoperative resection status. Secondary endpoints included postoperative morbidity, mortality, recurrence/progression-free, and overall survival. In total, 31.5% of patients were assigned to stage IIIa, 9.6% to stage IIIb, 47.9% to stage IVa, and 11% to stage IVb. In stages III a R0 resection was achieved in 53.3% of patients. In stages IV a R0/R1 resection was documented in 76.7% of patients. Surgical revision was necessary in 17.8% of patients. In-hospital mortality was 2.7%. Median recurrence/progression-free interval was 43 months (p = 0.19) with an overall survival of 79 months. The 5-year survival rate was 61.3%, respectively. Median survival after R2 resection was 25 months, significantly shorter than after R0 or R1 resection (115 months; p = 0.004). Advanced thymic tumors can be resected with an acceptable risk of complications and low mortality. In stage III as well as in stage IV the promising survival rates are dependent on the resection-status. MDPI 2021-09-08 /pmc/articles/PMC8471625/ /pubmed/34572742 http://dx.doi.org/10.3390/cancers13184516 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Markowiak, Till Ansari, Mohammed Khalid Afeen Neu, Reiner Schalke, Berthold Marx, Alexander Hofmann, Hans-Stefan Ried, Michael Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title | Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title_full | Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title_fullStr | Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title_full_unstemmed | Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title_short | Evaluation of Surgical Therapy in Advanced Thymic Tumors |
title_sort | evaluation of surgical therapy in advanced thymic tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471625/ https://www.ncbi.nlm.nih.gov/pubmed/34572742 http://dx.doi.org/10.3390/cancers13184516 |
work_keys_str_mv | AT markowiaktill evaluationofsurgicaltherapyinadvancedthymictumors AT ansarimohammedkhalidafeen evaluationofsurgicaltherapyinadvancedthymictumors AT neureiner evaluationofsurgicaltherapyinadvancedthymictumors AT schalkeberthold evaluationofsurgicaltherapyinadvancedthymictumors AT marxalexander evaluationofsurgicaltherapyinadvancedthymictumors AT hofmannhansstefan evaluationofsurgicaltherapyinadvancedthymictumors AT riedmichael evaluationofsurgicaltherapyinadvancedthymictumors |